Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib effect on BCRP and OATP1B1 in healthy males
NCT07158398Phase 1Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vimseltinib in tenosynovial giant cell tumor (TGCT), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Drug Concentration of rosuvastatin at 72 hours and Area Under the Concentration Versus Time Curve of rosuvastatin at 72 hours. Started Oct 2025; status: completed.
02
Drugs
vimseltinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT07158398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158398.